Zhiquan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhiquan Wang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Xin Chen
Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China
8 shared publicationsYan Lin
Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China
8 shared publicationsFabrice Yves Ndjana Lessomo
Department of Cardiology, Zhongnan Hospital, Wuhan University, No.169 Donghu Road, Wuchang District, Wuhan, 430071, Hubei, China
5 shared publicationsLihua Tian
Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China
5 shared publicationsChishimba Mukuka
Mansa Hospital, Mansa, Zambia
3 shared publicationsDodji Kossi Djakpo
Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China
3 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in Scientific Reports
Contemporary cardiometabolic and inflammation targeting therapies reduce residual cardiovascular risk in an endpoint harmonized meta analysis
Residual cardiovascular risk remains substantial despite contemporary preventive therapy. Multiple pharmacological strategies targeting metabolic, lipid-related, cardiorenal, and inflammatory pathways have shown cardiovascular benefit in randomized trials, but differences in endpoint definitions and composite outcome structures complicate cross-trial interpretation. We aimed to evaluate whether contemporary cardiometabolic and anti-inflammatory therapies are associated with lower major adverse cardiovascular event risk using an endpoint-harmonized framework. We conducted a systematic review and meta-analysis of randomized controlled trials evaluating sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, proprotein convertase subtilisin/kexin type 9 inhibitors, omega-3 fatty acid-based therapies, and anti-inflammatory agents. Databases were searched from inception through February 2026. The primary outcome was endpoint-harmonized major adverse cardiovascular events (MACE), defined as the trial-reported cardiovascular composite endpoint judged most comparable across studies according to prespecified harmonization rules. A prespecified sensitivity analysis was restricted to strict 3-point MACE, defined as cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Hazard ratios (HRs) were pooled on the log scale using random-effects models with restricted maximum likelihood estimation and Hartung–Knapp adjustment. Seventeen randomized trials involving 157,278 participants and 15,815 events contributed to the primary endpoint-harmonized analysis. Active therapy was associated with a lower risk of MACE than control (HR 0.84, 95% CI 0.79–0.88; I²=51%). In the sensitivity analysis restricted to strict 3-point MACE, 10 trials involving 98,973 participants and 9,067 events yielded a consistent pooled estimate with no observed heterogeneity (HR 0.83, 95% CI 0.80–0.86; I²=0%). Directionally consistent benefit was observed for sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and anti-inflammatory therapies. Estimates for proprotein convertase subtilisin/kexin type 9 inhibitors and omega-3 fatty acid-based therapies were based on limited trials and should be interpreted cautiously. No statistically significant effect modification by therapeutic class was detected, although the analysis was not designed to establish comparative equivalence across classes. Across randomized trials, contemporary cardiometabolic and anti-inflammatory therapies were associated with lower major adverse cardiovascular event risk. The consistency of findings in the strict 3-point MACE sensitivity analysis supports the robustness of the overall association. However, differences in heterogeneity and precision across therapeutic classes suggest that these therapies should not be assumed to be clinically interchangeable.
- 15 October 2026
- Published by Springer Nature in Scientific Reports
Open AccessContemporary cardiometabolic and inflammation targeting therapies reduce residual cardiovascular risk in an endpoint harmonized meta analysis
Residual cardiovascular risk remains substantial despite contemporary preventive therapy. Multiple pharmacological strategies targeting metabolic, lipid-related, cardiorenal, and inflammatory pathways have shown cardiovascular benefit in randomized trials, but differences in endpoint definitions and composite outcome structures complicate cross-trial interpretation. We aimed to evaluate whether contemporary cardiometabolic and anti-inflammatory therapies are associated with lower major adverse cardiovascular event risk using an endpoint-harmonized framework. We conducted a systematic review and meta-analysis of randomized controlled trials evaluating sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, proprotein convertase subtilisin/kexin type 9 inhibitors, omega-3 fatty acid-based therapies, and anti-inflammatory agents. Databases were searched from inception through February 2026. The primary outcome was endpoint-harmonized major adverse cardiovascular events (MACE), defined as the trial-reported cardiovascular composite endpoint judged most comparable across studies according to prespecified harmonization rules. A prespecified sensitivity analysis was restricted to strict 3-point MACE, defined as cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Hazard ratios (HRs) were pooled on the log scale using random-effects models with restricted maximum likelihood estimation and Hartung–Knapp adjustment. Seventeen randomized trials involving 157,278 participants and 15,815 events contributed to the primary endpoint-harmonized analysis. Active therapy was associated with a lower risk of MACE than control (HR 0.84, 95% CI 0.79–0.88; I²=51%). In the sensitivity analysis restricted to strict 3-point MACE, 10 trials involving 98,973 participants and 9,067 events yielded a consistent pooled estimate with no observed heterogeneity (HR 0.83, 95% CI 0.80–0.86; I²=0%). Directionally consistent benefit was observed for sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and anti-inflammatory therapies. Estimates for proprotein convertase subtilisin/kexin type 9 inhibitors and omega-3 fatty acid-based therapies were based on limited trials and should be interpreted cautiously. No statistically significant effect modification by therapeutic class was detected, although the analysis was not designed to establish comparative equivalence across classes. Across randomized trials, contemporary cardiometabolic and anti-inflammatory therapies were associated with lower major adverse cardiovascular event risk. The consistency of findings in the strict 3-point MACE sensitivity analysis supports the robustness of the overall association. However, differences in heterogeneity and precision across therapeutic classes suggest that these therapies should not be assumed to be clinically interchangeable.
- Open Access
- 21 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1952213
Association of metabolic indices with in-stent restenosis and its angiographic severity after drug-eluting stent implantation: a case-control study
Background: Metabolic abnormalities may contribute to in-stent restenosis (ISR) after percutaneous coronary intervention, but the comparative associations of commonly used metabolic indices with ISR within the same patient population remain incompletely characterized. Objective: To compare the associations of the triglyceride-glucose (TyG) index, atherogenic index of plasma (AIP), and metabolic score for insulin resistance (METS-IR) with angiographically detected ISR and its severity, and to explore potential heterogeneity according to sex and clinical presentation. Design: Retrospective, propensity-score-matched case-control study of patients undergoing follow-up coronary angiography between 2019 and 2024. Participants: The propensity-score-matched cohort comprised 774 patients, including 387 patients with ISR and 387 matched controls without ISR. Angiographic severity analyses were performed among the 387 matched patients with ISR. Main measures: TyG, AIP, and METS-IR were assessed separately in multivariable models. Model discrimination was evaluated using the area under the receiver operating characteristic curve (AUC), paired DeLong testing, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Sex- and clinical-presentation analyses were considered exploratory. Key results: The baseline clinical and procedural model yielded an AUC of 0.716 (95% CI 0.672–0.763) for ISR occurrence. Addition of TyG increased the AUC to 0.756 (95% CI 0.708–0.803; ΔAUC +0.040; paired DeLong p=0.003), while addition of AIP increased the AUC to 0.772 (95% CI 0.726–0.806; ΔAUC +0.056; p<0.001). Addition of METS-IR did not improve discrimination (AUC 0.716, 95% CI 0.671–0.748; p=0.642). Bootstrap analyses supported the incremental discrimination associated with TyG and AIP but not METS-IR. For ISR severity, addition of TyG or AIP produced only modest increases in AUC, neither of which was significant by paired DeLong testing. Formal interaction analyses did not demonstrate significant effect modification by sex, and analyses according to clinical presentation were limited by small subgroup sizes. Conclusions: In this retrospective matched cohort, TyG and AIP provided incremental discriminatory information for angiographically detected ISR beyond conventional clinical and procedural factors, whereas METS-IR provided little additional value. Evidence regarding angiographic severity was less robust, and findings across sex and clinical-presentation subgroups should be considered exploratory. Prospective external validation is required before these indices can be considered for clinical risk stratification.
- 21 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1952213
Open AccessAssociation of metabolic indices with in-stent restenosis and its angiographic severity after drug-eluting stent implantation: a case-control study
Background: Metabolic abnormalities may contribute to in-stent restenosis (ISR) after percutaneous coronary intervention, but the comparative associations of commonly used metabolic indices with ISR within the same patient population remain incompletely characterized. Objective: To compare the associations of the triglyceride-glucose (TyG) index, atherogenic index of plasma (AIP), and metabolic score for insulin resistance (METS-IR) with angiographically detected ISR and its severity, and to explore potential heterogeneity according to sex and clinical presentation. Design: Retrospective, propensity-score-matched case-control study of patients undergoing follow-up coronary angiography between 2019 and 2024. Participants: The propensity-score-matched cohort comprised 774 patients, including 387 patients with ISR and 387 matched controls without ISR. Angiographic severity analyses were performed among the 387 matched patients with ISR. Main measures: TyG, AIP, and METS-IR were assessed separately in multivariable models. Model discrimination was evaluated using the area under the receiver operating characteristic curve (AUC), paired DeLong testing, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Sex- and clinical-presentation analyses were considered exploratory. Key results: The baseline clinical and procedural model yielded an AUC of 0.716 (95% CI 0.672–0.763) for ISR occurrence. Addition of TyG increased the AUC to 0.756 (95% CI 0.708–0.803; ΔAUC +0.040; paired DeLong p=0.003), while addition of AIP increased the AUC to 0.772 (95% CI 0.726–0.806; ΔAUC +0.056; p<0.001). Addition of METS-IR did not improve discrimination (AUC 0.716, 95% CI 0.671–0.748; p=0.642). Bootstrap analyses supported the incremental discrimination associated with TyG and AIP but not METS-IR. For ISR severity, addition of TyG or AIP produced only modest increases in AUC, neither of which was significant by paired DeLong testing. Formal interaction analyses did not demonstrate significant effect modification by sex, and analyses according to clinical presentation were limited by small subgroup sizes. Conclusions: In this retrospective matched cohort, TyG and AIP provided incremental discriminatory information for angiographically detected ISR beyond conventional clinical and procedural factors, whereas METS-IR provided little additional value. Evidence regarding angiographic severity was less robust, and findings across sex and clinical-presentation subgroups should be considered exploratory. Prospective external validation is required before these indices can be considered for clinical risk stratification.
- Open Access
- 28 July 2026
- Published by Springer Nature in BMC Geriatrics
- Vol. 26 (1)
Feasibility of multidomain cardiovascular–kidney–metabolic biomarker assessment for in-hospital mortality in older heart failure inpatients: an exploratory retrospective cohort study
Cardiovascular-kidney-metabolic (CKM) dysfunction integrates cardiac, renal, metabolic, and inflammatory risk and is particularly relevant for older patien
- 28 July 2026
- Published by Springer Nature in BMC Geriatrics
- Vol. 26 (1)
Open AccessFeasibility of multidomain cardiovascular–kidney–metabolic biomarker assessment for in-hospital mortality in older heart failure inpatients: an exploratory retrospective cohort study
Cardiovascular-kidney-metabolic (CKM) dysfunction integrates cardiac, renal, metabolic, and inflammatory risk and is particularly relevant for older patien
- Open Access
- 16 December 2025
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 17 (1) , 449
Determinants of time to severe in-stent restenosis in patients with diabetes mellitus after drug-eluting coronary stenting
Despite advances in drug-eluting stents (DES), patients with diabetes mellitus (DM) remain at 1.5-2 times higher risk of in-stent restenosis (ISR) than non-diabetics. However, the temporal progression and predictors of severe ISR in this population are not well defined. A retrospective cohort analysis was conducted on 323 diabetic patients who underwent follow-up angiography after everolimus-eluting coronary stenting at a single center between May 2017 to December 2024. The primary outcome was the time to severe ISR (defined as ≥ 70% luminal narrowing). Demographic, clinical, metabolic (including METS-IR), and procedural (Gensini score, lesion characteristics) variables were analyzed. Cox regression identified predictors of accelerated restenosis, and a risk-stratification model was developed and validated internally. The median time to severe ISR was 7 months. Independent predictors included elevated D-dimer (HR = 1.001, p = 0.0004), BNP (HR = 1.001, p = 0.0001), METS-IR (HR = 1.378, p = 0.012), Gensini score (HR = 1.004, p = 0.032), and bilateral lesions (HR = 1.242, p = 0.03). Older age was identified as a protective factor, as was higher hemoglobin too. The risk model showed moderate discrimination (AUC = 0.702; sensitivity 68%; specificity 67%) and clinical utility on decision-curve analysis. Severe ISR manifests early in diabetics, driven by metabolic dysregulation, thrombotic activity, and procedural complexity. The validated risk-stratification model facilitates personalized surveillance and targeted interventions to mitigate the ISR burden on this vulnerable population.
- 16 December 2025
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 17 (1) , 449
Open AccessDeterminants of time to severe in-stent restenosis in patients with diabetes mellitus after drug-eluting coronary stenting
Despite advances in drug-eluting stents (DES), patients with diabetes mellitus (DM) remain at 1.5-2 times higher risk of in-stent restenosis (ISR) than non-diabetics. However, the temporal progression and predictors of severe ISR in this population are not well defined. A retrospective cohort analysis was conducted on 323 diabetic patients who underwent follow-up angiography after everolimus-eluting coronary stenting at a single center between May 2017 to December 2024. The primary outcome was the time to severe ISR (defined as ≥ 70% luminal narrowing). Demographic, clinical, metabolic (including METS-IR), and procedural (Gensini score, lesion characteristics) variables were analyzed. Cox regression identified predictors of accelerated restenosis, and a risk-stratification model was developed and validated internally. The median time to severe ISR was 7 months. Independent predictors included elevated D-dimer (HR = 1.001, p = 0.0004), BNP (HR = 1.001, p = 0.0001), METS-IR (HR = 1.378, p = 0.012), Gensini score (HR = 1.004, p = 0.032), and bilateral lesions (HR = 1.242, p = 0.03). Older age was identified as a protective factor, as was higher hemoglobin too. The risk model showed moderate discrimination (AUC = 0.702; sensitivity 68%; specificity 67%) and clinical utility on decision-curve analysis. Severe ISR manifests early in diabetics, driven by metabolic dysregulation, thrombotic activity, and procedural complexity. The validated risk-stratification model facilitates personalized surveillance and targeted interventions to mitigate the ISR burden on this vulnerable population.
- Open Access
- 19 April 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-9
Insight on the relationship between heart rate variability parameters and the risk of stroke among non-valvular paroxysmal atrial fibrillation patients
Identifying the risk of stroke in patients with atrial fibrillation (AF) presents a challenge, as existing tools such as the CHA2DS2-VASc score primarily emphasize medical history, affording relatively less attention to the electrocardiogram (ECG). Exploring HRV (heart rate-related variability) parameters could help refine risk prediction for thromboembolic ischemic stroke and enhance personalized management. This paper investigates how HRV parameters may inform the risk of acute ischemic stroke in atrial fibrillation patients. Data were retrospectively collected from Zhongnan Hospital’s electronic registry for patients with atrial fibrillation admitted in 2022. The sample was sorted into cases and controls based on specific inclusion and criteria. The outcome was the onset of acute ischemic stroke (AIS) in recurrent paroxysmal non-valvular atrial fibrillation. Cases and control data were analyzed using different statistical methods based on distribution, and the association between HRV parameters and the risk of stroke in paroxysmal atrial fibrillation was assessed. Binary logistic regression was utilized to assess a predictive model for stroke risk based on heart rate variability (HRV) parameters. A total of 3218 medical records with atrial fibrillation were retrieved. Out of 3218 medical records with atrial fibrillation, 192 were selected after screening, including 93 cases and 99 controls. The cohort comprised 93 females (50 cases) and 99 males (43 cases). Mean ages were 68.67 ± 1.95 for cases and 68.35 ± 1.19 for controls, with no significant difference (P > 0.05). Hypertension history was significantly more common in cases (P = 0.006), indicating a dependency between hypertension and acute ischemic stroke in non-valvular paroxysmal AF. SDNN mean rank was significantly lower in cases (P = 0.024), and LF was significantly reduced (P = 0.044). Other HRV parameters showed lower values in cases, but differences were not statistically significant. We found that AVTD (abnormal variation in the time domain) alone was significantly associated with acute ischemic stroke in non-valvular paroxysmal AF. While AVFD (abnormal variation in frequency domain) and AVA (abnormal variation in arrhythmogenicity) were not individually significant, a combined variable (CDV) from AVTD, AVFD, and AVA was also statistically significant (P = 0.029). In this model, SDNN, AVTD, history of hypertension, as well as the CHA2DS2-VASc score and the use of novel anticoagulant medicines (NOACS), were significant predictors in both univariate and multivariate analyses. At the same time, CDV was significant only in univariate analysis. These findings may suggest that HRV parameters may provide clues to the risk of acute ischemic stroke in non-valvular paroxysmal AF. This study found that abnormal variation in HRV parameters was more observed in patients with acute ischemic stroke. Then, unlike previous research, this study uniquely integrated multiple HRV parameters to develop novel indices such as AVTD, AVFD, AVA, and CDV, which somehow demonstrated a significant association with the risk of AIS. These new metrics, combined with conventional risk factors and CHA2DS2-VASc score, brought great improvement to the model prediction for AIS risk.
- 19 April 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-9
Open AccessInsight on the relationship between heart rate variability parameters and the risk of stroke among non-valvular paroxysmal atrial fibrillation patients
Identifying the risk of stroke in patients with atrial fibrillation (AF) presents a challenge, as existing tools such as the CHA2DS2-VASc score primarily emphasize medical history, affording relatively less attention to the electrocardiogram (ECG). Exploring HRV (heart rate-related variability) parameters could help refine risk prediction for thromboembolic ischemic stroke and enhance personalized management. This paper investigates how HRV parameters may inform the risk of acute ischemic stroke in atrial fibrillation patients. Data were retrospectively collected from Zhongnan Hospital’s electronic registry for patients with atrial fibrillation admitted in 2022. The sample was sorted into cases and controls based on specific inclusion and criteria. The outcome was the onset of acute ischemic stroke (AIS) in recurrent paroxysmal non-valvular atrial fibrillation. Cases and control data were analyzed using different statistical methods based on distribution, and the association between HRV parameters and the risk of stroke in paroxysmal atrial fibrillation was assessed. Binary logistic regression was utilized to assess a predictive model for stroke risk based on heart rate variability (HRV) parameters. A total of 3218 medical records with atrial fibrillation were retrieved. Out of 3218 medical records with atrial fibrillation, 192 were selected after screening, including 93 cases and 99 controls. The cohort comprised 93 females (50 cases) and 99 males (43 cases). Mean ages were 68.67 ± 1.95 for cases and 68.35 ± 1.19 for controls, with no significant difference (P > 0.05). Hypertension history was significantly more common in cases (P = 0.006), indicating a dependency between hypertension and acute ischemic stroke in non-valvular paroxysmal AF. SDNN mean rank was significantly lower in cases (P = 0.024), and LF was significantly reduced (P = 0.044). Other HRV parameters showed lower values in cases, but differences were not statistically significant. We found that AVTD (abnormal variation in the time domain) alone was significantly associated with acute ischemic stroke in non-valvular paroxysmal AF. While AVFD (abnormal variation in frequency domain) and AVA (abnormal variation in arrhythmogenicity) were not individually significant, a combined variable (CDV) from AVTD, AVFD, and AVA was also statistically significant (P = 0.029). In this model, SDNN, AVTD, history of hypertension, as well as the CHA2DS2-VASc score and the use of novel anticoagulant medicines (NOACS), were significant predictors in both univariate and multivariate analyses. At the same time, CDV was significant only in univariate analysis. These findings may suggest that HRV parameters may provide clues to the risk of acute ischemic stroke in non-valvular paroxysmal AF. This study found that abnormal variation in HRV parameters was more observed in patients with acute ischemic stroke. Then, unlike previous research, this study uniquely integrated multiple HRV parameters to develop novel indices such as AVTD, AVFD, AVA, and CDV, which somehow demonstrated a significant association with the risk of AIS. These new metrics, combined with conventional risk factors and CHA2DS2-VASc score, brought great improvement to the model prediction for AIS risk.
- Open Access
- 8 November 2023
- Published by Springer Nature in European Journal of Medical Research
- Vol. 28 (1) , 1-14
A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors
Newly approved cancer drugs called ICIs have shown remarkable success in improving patient survival rates, but they also have the potential for inflammatory and immune-related side effects, including those affecting the cardiovascular system. Research has been conducted to understand the development of these toxicities and identify risk factors. This review focuses on the characteristics of ICI-induced cardiotoxicity and discusses the reported risk factors. It is important for cardio-oncologists to understand the basic concepts of these drugs to better understand how cardiotoxicities occur. It might be hard to find reports, where all patients treated with ICIs had developed cardiac toxicity, because there could be other existing and variable factors that influence the likelihood or risk of developing cardiotoxicity during treatment. Various clinical parameters have been explored as potential risk factors, and further investigation is needed through large-scale studies.
- 8 November 2023
- Published by Springer Nature in European Journal of Medical Research
- Vol. 28 (1) , 1-14
Open AccessA comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors
Newly approved cancer drugs called ICIs have shown remarkable success in improving patient survival rates, but they also have the potential for inflammatory and immune-related side effects, including those affecting the cardiovascular system. Research has been conducted to understand the development of these toxicities and identify risk factors. This review focuses on the characteristics of ICI-induced cardiotoxicity and discusses the reported risk factors. It is important for cardio-oncologists to understand the basic concepts of these drugs to better understand how cardiotoxicities occur. It might be hard to find reports, where all patients treated with ICIs had developed cardiac toxicity, because there could be other existing and variable factors that influence the likelihood or risk of developing cardiotoxicity during treatment. Various clinical parameters have been explored as potential risk factors, and further investigation is needed through large-scale studies.
- Open Access
- 29 March 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1080998
Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis
Objective: Recently, several researchers have reported the incidence of cardiac-related toxicities occurring with nivolumab (Opdivo) and pembrolizumab (Keytruda). There is still a need for balance between oncology treatment efficacy and reduction of cardiotoxicity burden in immune checkpoint inhibitor (ICI)-treated patients. Thus, the primary aim was to determine whether pembrolizumab or nivolumab would present with a greater risk for cardiotoxicity reports.Materials and methods: This meta-analysis was performed with respect to the MOOSE reporting guidelines. Studies were retrieved by searching PubMed, Embase, and Google Scholar; the search terms were Keytruda or Pembrolizumab, PD1 inhibitors, anti-PD1 drugs, Nivolumab or Opdivo, and cardiotoxicities or cardiac toxicity. The study was restricted to original articles investigating ICI-induced cardiac immune-related adverse events (irAEs). The targeted population was cancer patients treated with either pembrolizumab or nivolumab monotherapy, of which those with records of any cardiac events following the therapy were labeled as events. The measures used to achieve the comparison were descriptive proportions, probabilities, and meta-analysis pooled odds ratios (ORs).Results: Fifteen studies were included in this meta-analysis. Nivolumab accounted for 55.7% cardiotoxicity and pembrolizumab, for 27.31% (P = 0.027). The meta-analysis was based on the Mantel–Haenszel method, and the random-effect model yielded a pooled OR = 0.73 (95% CI [0.43–1.23] P = 0.24), with considerable heterogeneity (I2 = 99% P = 0). Hence, the difference in cardiotoxicity odds risk between pembrolizumab and nivolumab was not statistically significant. On subgroup analysis based on cardiotoxicity type, the “myocarditis” subgroup in which there was no statistical heterogeneity was associated with a significant cardiotoxicity risk increase with pembrolizumab (OR = 1.30 [1.07;1.59], P< 0.05; I2 = 0%, Ph = 0.4).Conclusion: To our knowledge, this is the first meta-analysis to compare the cardiotoxicity potentials of nivolumab and pembrolizumab. In contrast to previous reports, the overall findings here demonstrated that nivolumab-induced cardiotoxicity was more commonly reported in the literature than pembrolizumab; however, myocarditis seemed more likely to occur with pembrolizumab therapy.
- 29 March 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1080998
Open AccessComparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis
Objective: Recently, several researchers have reported the incidence of cardiac-related toxicities occurring with nivolumab (Opdivo) and pembrolizumab (Keytruda). There is still a need for balance between oncology treatment efficacy and reduction of cardiotoxicity burden in immune checkpoint inhibitor (ICI)-treated patients. Thus, the primary aim was to determine whether pembrolizumab or nivolumab would present with a greater risk for cardiotoxicity reports.Materials and methods: This meta-analysis was performed with respect to the MOOSE reporting guidelines. Studies were retrieved by searching PubMed, Embase, and Google Scholar; the search terms were Keytruda or Pembrolizumab, PD1 inhibitors, anti-PD1 drugs, Nivolumab or Opdivo, and cardiotoxicities or cardiac toxicity. The study was restricted to original articles investigating ICI-induced cardiac immune-related adverse events (irAEs). The targeted population was cancer patients treated with either pembrolizumab or nivolumab monotherapy, of which those with records of any cardiac events following the therapy were labeled as events. The measures used to achieve the comparison were descriptive proportions, probabilities, and meta-analysis pooled odds ratios (ORs).Results: Fifteen studies were included in this meta-analysis. Nivolumab accounted for 55.7% cardiotoxicity and pembrolizumab, for 27.31% (P = 0.027). The meta-analysis was based on the Mantel–Haenszel method, and the random-effect model yielded a pooled OR = 0.73 (95% CI [0.43–1.23] P = 0.24), with considerable heterogeneity (I2 = 99% P = 0). Hence, the difference in cardiotoxicity odds risk between pembrolizumab and nivolumab was not statistically significant. On subgroup analysis based on cardiotoxicity type, the “myocarditis” subgroup in which there was no statistical heterogeneity was associated with a significant cardiotoxicity risk increase with pembrolizumab (OR = 1.30 [1.07;1.59], P< 0.05; I2 = 0%, Ph = 0.4).Conclusion: To our knowledge, this is the first meta-analysis to compare the cardiotoxicity potentials of nivolumab and pembrolizumab. In contrast to previous reports, the overall findings here demonstrated that nivolumab-induced cardiotoxicity was more commonly reported in the literature than pembrolizumab; however, myocarditis seemed more likely to occur with pembrolizumab therapy.
- Open Access
- 4 February 2023
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 23 (1) , 1-8
The relationship between leukocyte to albumin ratio and atrial fibrillation severity
Background: An increased leukocyte count is a sign of inflammation and has been demonstrated to be a predisposing factor and complication of atrial fibrillation. Similarly, albumin, the major protein in the serum, is also considered an acute phase reactant protein that has osmotic and anti-inflammatory properties, and a low albumin level is a known factor associated with severity in many pathologies, including atrial fibrillation. The neutrophil percentage-to-albumin ratio (NPAR) and other emerging leukocyte counts/albumin ratios have been reliable systemic inflammation-based predictors of mortality and complications in various diseases, but they have not yet been used with atrial fibrillation. This study’s aim was to explore whether the leukocyte to albumin ratio could also serve as a useful index in estimating atrial fibrillation severity, including the severity of atrial fibrillation secondary to stroke, to provide a new and more objective tool than the conventional and medical history-based CHA2DS2–VASc score. Materials and methods: Data were retrospectively collected from the Wuhan University Zhongnan Hospital database from January 1st to December 31st, 2021. The patients were classified into 2 groups: Group 1-low severity and Group 2- moderate to high severity, and diverse statistical analyses were conducted to evaluate the relationship between the leukocyte-to-albumin ratio and AF severity. Results: Only 2329 test subjects met the inclusion criteria. We had 727 test subjects (381 males and 346 females) categorized into the low severity cohort and 1601 test subjects (932 males and 670 females) in the moderate to high severity group. The difference in mean age between the two groups was significant (95% CI [−2.682 to −0.154] p = 0.028), and the difference in the LAR mean rank between the two groups was significant (p = 0.00). The Chi-square test of association yielded the following results: the relationship between the LAR level and category of severity was statistically significant (p = 0.00), and the Mantel‒Haenszel statistic association odds ratio was OR = 0.657. 95% CI OR [0.549–0.787] p = 0.000. The association between sex and atrial fibrillation severity also reached statistical significance. However, sex and LAR were found to be independent factors in atrial fibrillation (Chi-square p value = 0.564). Conclusion: It has been demonstrated throughout this investigation that the leukocyte to albumin ratio could provide key clues in clinical practice and contribute to thromboembolism risk assessment in the setting of atrial fibrillation.
- 4 February 2023
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 23 (1) , 1-8
Open AccessThe relationship between leukocyte to albumin ratio and atrial fibrillation severity
Background: An increased leukocyte count is a sign of inflammation and has been demonstrated to be a predisposing factor and complication of atrial fibrillation. Similarly, albumin, the major protein in the serum, is also considered an acute phase reactant protein that has osmotic and anti-inflammatory properties, and a low albumin level is a known factor associated with severity in many pathologies, including atrial fibrillation. The neutrophil percentage-to-albumin ratio (NPAR) and other emerging leukocyte counts/albumin ratios have been reliable systemic inflammation-based predictors of mortality and complications in various diseases, but they have not yet been used with atrial fibrillation. This study’s aim was to explore whether the leukocyte to albumin ratio could also serve as a useful index in estimating atrial fibrillation severity, including the severity of atrial fibrillation secondary to stroke, to provide a new and more objective tool than the conventional and medical history-based CHA2DS2–VASc score. Materials and methods: Data were retrospectively collected from the Wuhan University Zhongnan Hospital database from January 1st to December 31st, 2021. The patients were classified into 2 groups: Group 1-low severity and Group 2- moderate to high severity, and diverse statistical analyses were conducted to evaluate the relationship between the leukocyte-to-albumin ratio and AF severity. Results: Only 2329 test subjects met the inclusion criteria. We had 727 test subjects (381 males and 346 females) categorized into the low severity cohort and 1601 test subjects (932 males and 670 females) in the moderate to high severity group. The difference in mean age between the two groups was significant (95% CI [−2.682 to −0.154] p = 0.028), and the difference in the LAR mean rank between the two groups was significant (p = 0.00). The Chi-square test of association yielded the following results: the relationship between the LAR level and category of severity was statistically significant (p = 0.00), and the Mantel‒Haenszel statistic association odds ratio was OR = 0.657. 95% CI OR [0.549–0.787] p = 0.000. The association between sex and atrial fibrillation severity also reached statistical significance. However, sex and LAR were found to be independent factors in atrial fibrillation (Chi-square p value = 0.564). Conclusion: It has been demonstrated throughout this investigation that the leukocyte to albumin ratio could provide key clues in clinical practice and contribute to thromboembolism risk assessment in the setting of atrial fibrillation.
- Open Access
- 17 December 2022
- Published by Elsevier in Current Problems in Cardiology
- Vol. 48 (4) , 101556
The BNP to Albumin Ratio and Heart Rate in Stroke Complicating Atrial Fibrillation
- 17 December 2022
- Published by Elsevier in Current Problems in Cardiology
- Vol. 48 (4) , 101556
Open AccessThe BNP to Albumin Ratio and Heart Rate in Stroke Complicating Atrial Fibrillation
- Open Access
- 7 August 2020
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 40 (8)
Blood routine test in mild and common 2019 coronavirus (COVID-19) patients
The new 2019 coronavirus disease (COVID-19), according to the World Health Organization (WHO), has been characterized as a pandemic. As more is being discovered about this virus, we aim to report findings of the complete blood count (CBC) of COVID-19 patients. This would serve in providing physicians with important knowledge on the changes that can be expected from the CBC of mild and normal COVID-19 patients. A total of 208 mild and common patients were admitted at the Dongnan Hospital located in the city of Xiaogan, Hubei, China. The CBCs of these patients, following a confirmed diagnosis of COVID-19, were retrospectively analyzed and a significant P<0.05 was found after a full statistical analysis was conducted using the Statistical Package for the Social Sciences (IBM SPSS). CBC analysis revealed changes in the levels of red blood cells (RBCs), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), and C-reactive protein (CRP). Clinicians should expect similar findings when dealing with the new COVID-19.
- 7 August 2020
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 40 (8)
Open AccessBlood routine test in mild and common 2019 coronavirus (COVID-19) patients
The new 2019 coronavirus disease (COVID-19), according to the World Health Organization (WHO), has been characterized as a pandemic. As more is being discovered about this virus, we aim to report findings of the complete blood count (CBC) of COVID-19 patients. This would serve in providing physicians with important knowledge on the changes that can be expected from the CBC of mild and normal COVID-19 patients. A total of 208 mild and common patients were admitted at the Dongnan Hospital located in the city of Xiaogan, Hubei, China. The CBCs of these patients, following a confirmed diagnosis of COVID-19, were retrospectively analyzed and a significant P<0.05 was found after a full statistical analysis was conducted using the Statistical Package for the Social Sciences (IBM SPSS). CBC analysis revealed changes in the levels of red blood cells (RBCs), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), and C-reactive protein (CRP). Clinicians should expect similar findings when dealing with the new COVID-19.